Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ensysce Biosciences Inc
(OP:
ENSCW
)
0.0020
UNCHANGED
Streaming Delayed Price
Updated: 3:56 PM EST, Jan 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ensysce Biosciences Inc
< Previous
1
2
Next >
Ensysce Biosciences Receives Positive Nasdaq Listing Determination
November 07, 2024
Via
ACCESSWIRE
Ensysce Biosciences Announces Leadership Team’s Participation in the Annual Pain Therapeutics Summit
October 08, 2024
Via
ACCESSWIRE
Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries
October 02, 2024
Via
ACCESSWIRE
Ensysce Biosciences Presenting at Upcoming Meetings
September 24, 2024
Via
ACCESSWIRE
Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024
September 13, 2024
Via
ACCESSWIRE
Ensysce Biosciences Provides Mid-Year 2024 Update
July 23, 2024
Via
ACCESSWIRE
Ensysce Biosciences Hosts IASP 2024 Symposium and Presents Clinical Dataset
July 09, 2024
Via
ACCESSWIRE
Ensysce Biosciences Announces Partnership to Scale and Manufacture New Drug Candidate
June 25, 2024
Via
ACCESSWIRE
Ensysce Biosciences Announces Major Milestone for Opioid Use Disorder Program
June 06, 2024
Via
ACCESSWIRE
Ensysce Biosciences to Participate in the EPHMRA 2024 Annual Meeting
June 03, 2024
Via
ACCESSWIRE
Ensysce Biosciences Continues Collaboration to Advance the Clinical Development of Innovative Overdose Protection Platform
May 20, 2024
Via
ACCESSWIRE
Ensysce Biosciences Reports First Quarter 2024 Financial Results
May 13, 2024
Via
ACCESSWIRE
Ensysce Biosciences' Presentation from the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference Published
April 19, 2024
Via
ACCESSWIRE
Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
April 09, 2024
Via
ACCESSWIRE
Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript
February 15, 2024
Via
ACCESSWIRE
Ensysce Biosciences Announces Enrollment Completion for PF614-201 Clinical Study
November 16, 2023
Via
ACCESSWIRE
Ensysce Biosciences Secures $1.7 Million Convertible Note Financing
October 24, 2023
Via
ACCESSWIRE
Ensysce Biosciences to Participate in Upcoming Industry Events
June 06, 2023
Via
ACCESSWIRE
Ensysce Biosciences to Present Groundbreaking Oral Overdose Protection for Opioids at the 5th Annual NIH HEAL Meeting
January 25, 2024
Via
ACCESSWIRE
Ensysce Biosciences Issues 2024 Shareholder Letter
January 08, 2024
Via
ACCESSWIRE
Ensysce Biosciences and Quotient Sciences to Present MPAR(R) Overdose Protection Platform at Upcoming CRS 2023 Annual Meeting and Expo
June 27, 2023
Via
ACCESSWIRE
Ensysce Biosciences Announces the Distribution of Series A Preferred Stock to Holders of Its Common Stock
February 01, 2023
Via
ACCESSWIRE
Ensysce Biosciences Announces Initiation of Final Stage of Groundbreaking Opioid Overdose Protection Phase 1 Study
January 25, 2023
Via
ACCESSWIRE
Ensysce Biosciences Announces Successful Completion of Clinical Portion of Oral Human Abuse Potential Trial
January 04, 2023
Via
ACCESSWIRE
Ensysce Biosciences Announces Data from PF614-MPAR-101-Part A Successfully Demonstrating Opioid Overdose Protection
December 19, 2022
Via
ACCESSWIRE
Ensysce Biosciences to Present at Diamond Equity Research 2023 Virtual Emerging Growth Invitational
January 23, 2023
Via
ACCESSWIRE
Ensysce Biosciences Issues 2023 Shareholder Letter
January 11, 2023
Via
ACCESSWIRE
Ensysce Biosciences Announces Pricing of $4.1 Million Public Offering
December 07, 2022
Via
ACCESSWIRE
Ensysce Biosciences Announces Completion of Clinical Portion of Overdose Protection Trial PF614-MPAR-101-Part A
December 05, 2022
Via
ACCESSWIRE
Ensysce Biosciences Reports Third Quarter 2022 Financial Results
November 14, 2022
Via
ACCESSWIRE
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
